363 related articles for article (PubMed ID: 28234925)
1. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas.
Ramachandran RK; Sørensen MD; Aaberg-Jessen C; Hermansen SK; Kristensen BW
PLoS One; 2017; 12(2):e0172234. PubMed ID: 28234925
[TBL] [Abstract][Full Text] [Related]
2. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors.
Nakada M; Nakamura H; Ikeda E; Fujimoto N; Yamashita J; Sato H; Seiki M; Okada Y
Am J Pathol; 1999 Feb; 154(2):417-28. PubMed ID: 10027400
[TBL] [Abstract][Full Text] [Related]
3. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
Nakada M; Kita D; Futami K; Yamashita J; Fujimoto N; Sato H; Okada Y
J Neurosurg; 2001 Mar; 94(3):464-73. PubMed ID: 11235952
[TBL] [Abstract][Full Text] [Related]
4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
5. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas.
Thorns V; Walter GF; Thorns C
Anticancer Res; 2003; 23(5A):3937-44. PubMed ID: 14666700
[TBL] [Abstract][Full Text] [Related]
6. Expression of matrix metalloproteinases and their inhibitors in human brain tumors.
Kachra Z; Beaulieu E; Delbecchi L; Mousseau N; Berthelet F; Moumdjian R; Del Maestro R; Béliveau R
Clin Exp Metastasis; 1999; 17(7):555-66. PubMed ID: 10845554
[TBL] [Abstract][Full Text] [Related]
7. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.
Nakagawa T; Kubota T; Kabuto M; Sato K; Kawano H; Hayakawa T; Okada Y
J Neurosurg; 1994 Jul; 81(1):69-77. PubMed ID: 8207529
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2.
Zhang K; Li C; Liu Y; Li L; Ma X; Meng X; Feng D
Neuroradiology; 2007 Nov; 49(11):913-9. PubMed ID: 17763847
[TBL] [Abstract][Full Text] [Related]
9. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-2 and -9 expression in astrocytic tumors.
Kunishio K; Okada M; Matsumoto Y; Nagao S
Brain Tumor Pathol; 2003; 20(2):39-45. PubMed ID: 14756439
[TBL] [Abstract][Full Text] [Related]
11. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
[TBL] [Abstract][Full Text] [Related]
12. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms.
Jäälinojä J; Herva R; Korpela M; Höyhtyä M; Turpeenniemi-Hujanen T
J Neurooncol; 2000; 46(1):81-90. PubMed ID: 10896208
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas.
Lucio-Eterovic AK; Cortez MA; Valera ET; Motta FJ; Queiroz RG; Machado HR; Carlotti CG; Neder L; Scrideli CA; Tone LG
BMC Cancer; 2008 Aug; 8():243. PubMed ID: 18713462
[TBL] [Abstract][Full Text] [Related]
15. Expression and Prognostic Value of Oct-4 in Astrocytic Brain Tumors.
Krogh Petersen J; Jensen P; Dahl Sørensen M; Winther Kristensen B
PLoS One; 2016; 11(12):e0169129. PubMed ID: 28030635
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases in human gliomas: activation of matrix metalloproteinase-2 (MMP-2) may be correlated with membrane-type-1 matrix metalloproteinase (MT1-MMP) expression.
Hur JH; Park MJ; Park IC; Yi DH; Rhee CH; Hong SI; Lee SH
J Korean Med Sci; 2000 Jun; 15(3):309-14. PubMed ID: 10895974
[TBL] [Abstract][Full Text] [Related]
17. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
18. NRF2, DJ1 and SNRX1 and their prognostic impact in astrocytic gliomas.
Haapasalo J; Nordfors K; Granberg KJ; Kivioja T; Nykter M; Haapasalo H; Soini Y
Histol Histopathol; 2018 Aug; 33(8):791-801. PubMed ID: 29441509
[TBL] [Abstract][Full Text] [Related]
19. Activated leukocyte cell adhesion molecule is expressed in neuroepithelial neoplasms and decreases with tumor malignancy, matrix metalloproteinase 2 expression, and absence of IDH1R132H mutation.
Allmendinger O; Trautmann K; Mittelbronn M; Waidelich J; Meyermann R; Tatagiba M; Schittenhelm J
Hum Pathol; 2012 Aug; 43(8):1289-99. PubMed ID: 22304788
[TBL] [Abstract][Full Text] [Related]
20. Expression of the Annexin A1 and its correlation with matrix metalloproteinases and the receptor for formylated peptide-2 in diffuse astrocytic tumors.
Tadei MB; Mayorquim MV; de Souza CB; de Souza Costa S; Possebon L; Souza HR; Iyomasa-Pilon MM; Geromel MR; Girol AP
Ann Diagn Pathol; 2018 Dec; 37():62-66. PubMed ID: 30286327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
